Volumen: 8 # Number : 1
Publication Date : Enero - Abril Year: 2004
Authors: Jorge D Korin , Pablo Porterie, Lucía C Kordich
Abstract: After more than 20 years of clinical use of low
molecular-weight heparins (LMWH), controversies still
persist concerning their interchangeability. The professional
that indicates a LMWH should base his decision on
references of the medical literature and cost-effectiveness
analysis. However, our economic situation frequently reduces
the possibility to choose to the availability of the
products. In our country, it is either possible not to have
any LMWH in stock, two or more to select, or even two
different brands of the same LMWH. In the latter, it is
important to consider the different sources of the two
drugs, the scarcity of clinical trials published about the
latest one introduced in the market and the possibility to
afford a comparative study for efficacy and safety.
Therefore, we decided to compare the differences
achieved in heparin levels, aPTT and Thrombin Time, in 40
volunteers 2 hours after a subcutaneous injection of two
different brands of enoxaparin, within a one-week interval.
Similar degree of prolongation of the aforementioned tests
was observed with both sources of enoxaparin. Being a
direct comparison with relevant clinical end points more
informative, the large amount of patients required for such
trial precludes its implementatio
Key words:
Pages : 9-13
|
